Huan Xie

Huan Xie

Auto-generated profile, based on publicly available information

Huan Xie

Department of Hematology, Army Medical Center of PLA, Chongqing, China

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 April 2018 in Leukemia & Lymphoma
Verified
Journal Article
Closed access
LLLin Liu
Lin Liu
JWJinhuan Wang
Jinhuan Wang
YJYanan Jiang
Yanan Jiang
HXHuan Xie
Huan Xie
XTXiaoqiong Tang
Xiaoqiong Tang
ZZZhigang Zhao
Zhigang Zhao
The clinical impact of ecotropic viral integration site 1 (EVI1) expression status in myelodysplastic syndromes (MDS) is poorly defined. Here, we investigate the expression of EVI1 and its associated clinical and cytogenetic characteristics in 398 MDS patients. High EVI1 levels (EVI1high) were found more frequently in Higher-risk MDS patients. Other cytogenetic abnormalities over-represented among EVI1high cases included complex karyotype, del(5q), monosomy 7, and 12q-compared with EVI1low MDS. No specific gene mutation was found different between EVI1high and EVI1low patients, except for a high proportion of TP53 mutation in the EVI1high group. For EVIhigh patients, mean number of gene mutations was higher than that in EVI1low patients. No definite correlation was found between EVI1 expression and MDS prognosis. However, for Higher-risk MDS patients, EVI1high patients have poorer survival rate compared with EVI1low patients. Moreover, EVI1high was an adverse prognostic marker for MDS with excess blasts subtype. The addition of EVI1 could deteriorate the survival of MDS patients with chromosome 3 abnormalities, del(5q-) or monosomy 7. Taken together, EVI1 overexpression is a poor prognostic marker for higher-risk MDS group and could be included in risk stratification for MDS patients.

13 January 2024 in BMC Immunology
Verified
Journal Article
Open access
PDF file
HXHuan Xie
Huan Xie
JZJing Zhang
Jing Zhang
RLRan Luo
Ran Luo
YQYan Qi
Yan Qi
YLYizhang Lin
Yizhang Lin
ZDZeng Dongfeng
Zeng Dongfeng
Background: The ability of generating effective humoral immune responses to SARS-CoV-2 infection has not been clarified in lymphoma patients. The study aimed to investigate the antibody (Ab) production after SARS-Cov-2 infection and clarify the factors affecting the Ab generation in these patients. Patients & methods: 80 lymphoma patients and 51 healthy controls were included in this prospective observational study. Clinical factors and treatment regimens affecting Ab positive rate (APR) and Ab levels were analyzed by univariate and multivariate methods. Results: The anti-SARS-CoV-2 IgG APR and Ab levels in lymphoma patients were significantly lower than those in healthy controls. Lymphoma patients with COVID-19 vaccination had significantly higher APR and Ab levels compared with those without vaccination. Additionally, the use of dexamethasone for COVID-19 treatment had a negative impact on Ab levels. For the impact of treatment regimens on the APR and Ab levels, the results showed that patients treated with ≥ 6 times CD20 monoclonal Ab (mAb) and patients treated with autologous hematopoietic stem cell transplantation (ASCT) prior to infection produced a statistically lower APR and Ab levels compared with those treated with 1–5 times CD20 mAb and those treated without ASCT, respectively. Furthermore, multiple regression analysis indicated that the number of anti-CD20 treatment was an independent predictor for both APR and Ab levels. Conclusions: Humoral immune response to SARS-CoV-2 infection was impaired in lymphoma patients partly due to anti-CD20 and ASCT treatment. COVID-19 vaccination may be more needed for these patients.

1 May 2023 in Annals of Laboratory Medicine
Verified
Journal Article
Open access
PDF file
HXHuan Xie
Huan Xie
ZZZhongyue Zhao
Zhongyue Zhao
ZDZeng Dongfeng
Zeng Dongfeng
Huan Xie, M.D., Zhongyue Zhao, B.S., and Dongfeng Zeng, Ph.D.. Ann Lab Med 2023;43:295-8. https://doi.org/10.3343/alm.2023.43.3.295

21 August 2026 in Archives of Medical Science
Verified
Journal Article
Open access
PDF file
HXHuan Xie
Huan Xie
RLRan Luo
Ran Luo
ZDZeng Dongfeng
Zeng Dongfeng